In summary, the most significant thing was that we confirmed novel HDAC6 inhibitor F7 alleviated acute renal function against rhabdomyolysis-induced AKI and selective inhibition of HDAC6 activity was a promising strategy for the treatment of AKI. The gene discussed is HDAC6; the disease is acute kidney injury.